0 0 Bensen Pharma Limited 14844370 false 2025-04-01 2026-03-31 2026-03-31 The principal activity of the company is Research and experimental development on biotechnology Digita Accounts Production Advanced 6.30.9574.0 true false 14844370 2025-04-01 2026-03-31 14844370 2026-03-31 14844370 core:CurrentFinancialInstruments 2026-03-31 14844370 core:CurrentFinancialInstruments core:WithinOneYear 2026-03-31 14844370 core:AdditionsToInvestments 2026-03-31 14844370 core:ParentEntities 2026-03-31 14844370 bus:SmallEntities 2025-04-01 2026-03-31 14844370 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 14844370 bus:FilletedAccounts 2025-04-01 2026-03-31 14844370 bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 14844370 bus:RegisteredOffice 2025-04-01 2026-03-31 14844370 bus:Director1 2025-04-01 2026-03-31 14844370 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 14844370 bus:Agent1 2025-04-01 2026-03-31 14844370 core:ParentEntities 2025-04-01 2026-03-31 14844370 countries:UnitedKingdom 2025-04-01 2026-03-31 14844370 2025-03-31 14844370 core:ParentEntities 2025-03-31 14844370 2024-04-01 2025-03-31 14844370 2025-03-31 14844370 core:CurrentFinancialInstruments 2025-03-31 14844370 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 14844370 core:ParentEntities 2025-03-31 14844370 core:ParentEntities 2024-04-01 2025-03-31 14844370 2024-03-31 14844370 core:ParentEntities 2024-03-31 xbrli:pure iso4217:GBP

Registration number: 14844370

Bensen Pharma Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2026

 

Bensen Pharma Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 6

 

Bensen Pharma Limited

Company Information

Director

A R Boyce

Registered office

Ruffles Barn Brookside
Dalham
Newmarket
England
CB8 8TG

Accountants

LJ Mills FCA Lower Church Farmhouse
Cockfield
Bury St Edmunds
Suffolk
IP30 0LA

 

Bensen Pharma Limited

(Registration number: 14844370)
Balance Sheet as at 31 March 2026

Note

2026
£

2025
£

Fixed Assets

 

Investments

4

80,357

80,357

Current assets

 

Debtors

5

27,144

28,014

Cash at bank and in hand

 

390

276

 

27,534

28,290

Creditors: Amounts falling due within one year

6

(315,514)

(288,122)

Net current liabilities

 

(287,980)

(259,832)

Net liabilities

 

(207,623)

(179,475)

Capital and Reserves

 

Called up share capital

285

285

Retained Earnings

(207,908)

(179,760)

Shareholders' deficit

 

(207,623)

(179,475)

For the financial year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 18 August 2026
 

.........................................
A R Boyce
Director

 

Bensen Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

1

General information

The company is a private company limited by share capital, incorporated in United Kingdom.

The address of its registered office is:
Ruffles Barn Brookside
Dalham
Newmarket
CB8 8TG
England

These financial statements were authorised for issue by the director on 18 August 2026.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The financial statements are presented in Sterling, which is the functional currency of the company.

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

 

Bensen Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade Debtors

Trade Debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade Debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade Creditors

Trade Creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade Creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 0 (2025 - 0).

4

Investments

2026
£

2025
£

Investments in subsidiaries

80,357

80,357

 

Bensen Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

Subsidiaries

£

Cost or valuation

Additions

80,357

Provision

Carrying amount

At 31 March 2026

80,357

At 31 March 2025

80,357

5

Debtors

Current

2026
£

2025
£

Prepayments

26,679

27,706

Other debtors

465

308

 

27,144

28,014

6

Creditors

Creditors: amounts falling due within one year

2026
£

2025
£

Due within one year

Trade Creditors

440

409

Accruals and deferred income

1,250

1,250

Other creditors

313,824

286,463

315,514

288,122

7

Related party transactions

Loans from related parties

2026

Parent
£

Total
£

At start of period

284,440

284,440

At end of period

284,440

284,440

 

Bensen Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2026

2025

Parent
£

Total
£

At start of period

193,000

193,000

Advanced

91,440

91,440

At end of period

284,440

284,440

Terms of loans from related parties

The loan from Bensen Holdings is interest free. At the year end Bensen Holdings have provided assurance of the ongoing support of the company, as such the accounts have been prepared on a going concern basis.